- Home
- KITT vs BIAF Comparison
KITT vs BIAF Comparison
Compare KITT & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KITT | BIAF |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 6.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | KITT | BIAF |
|---|---|---|
| Price | $1.21 | $1.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.2M | 108.8K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,688,840.00 | ★ $6,776,739.00 |
| Revenue This Year | $2,936.06 | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.38 | N/A |
| 52 Week Low | $0.71 | $1.25 |
| 52 Week High | $54.36 | $46.53 |
Technical Indicators
Market Signals| Indicator | KITT | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 46.56 |
| Support Level | $0.71 | $1.34 |
| Resistance Level | $1.70 | $1.54 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 49.49 | 63.05 |
Price Performance
Historical ComparisonAbout KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.